AbbVie IncABBV
▲ PositiveTechnologyrelevance
Phase 3 trial met primary endpoint with significant PFS improvement
Impact on stocks 2
Biotech & Genomic Medicine▲ · 1 stocks
AbbVie IncHealth Care▲ · 1 stocks
Genmab ASGMAB
▲ PositiveTechnologyrelevance
Co-developer of epcoritamab; positive trial results benefit Genmab
Theme Impact 2
Off-coverage companies
Related news
▼
Novo Rebrands as Novo, Lilly Wins FDA Nod, GE HealthCare Nears $1B Sofie Deal
Novo Nordisk will shorten its name to Novo and update its logo, with its trademark bull shifting to face right, as the Danish drugmaker battles Eli Lilly for dominance in the obesity-drug market. CEO Mike Doustdar is pushing to make Novo leaner and more competitive, and the company will detail its updated corporate strategy at a Capital Markets Day on September 21 in London. Separately, Eli Lilly said the U.S. FDA granted full approval for an all-oral regimen combining its estrogen receptor antagonist Inluriyo and kinase inhibitor Verzenio as a late-line option for adults with estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation whose disease progressed after one or more prior endocrine therapies. GE HealthCare Technologies is in advanced talks to acquire Sofie Biosciences for about $1 billion, a deal that would expand its presence in radioactive diagnostic agents used with medical scans, according to the Financial Times. Summit Therapeutics said ivonescimab reduced the risk of death by 27% versus Merck's Keytruda in a late-stage lung cancer trial, with median overall survival of 30.8 months versus 22.6 months. Medtronic launched an exchange offer to split off at least 80.1% of MiniMed Group, allowing shareholders to exchange ordinary shares for MiniMed common stock at a 7% discount.
Agenus Fair Value Rises to US$26.33 on Trial Updates and Fresh Financing
Agenus now carries an updated implied fair value of about US$26.33 per share, up from US$19.50, a roughly 35% increase tied to trial updates and fresh financing. The higher target reflects recent Street commentary on the botensilimab plus balstilimab program in microsatellite stable colorectal cancer and on new capital that changes how investors weigh financing risk. Chardan, H.C. Wainwright and B. Riley have all assigned Buy ratings on the stock in 2026, with price target revisions to US$30, US$25 and US$14. H.C. Wainwright factors in an assumed issuance of 23 million shares tied to an US$85 million upfront financing payment, highlighting ongoing dilution and funding risk. The fair value update also reflects revenue growth assumptions of a decline of about 1.37%, a net profit margin easing from about 17.91% to about 17.63%, a future P/E shifting from about 58.6x to about 80.6x, and a discount rate moving from about 7.60% to about 7.69%.
▲2
Akeso Wins China Phase I Clearance for AK158D1 Bispecific ADC
Akeso has secured Phase I clinical trial clearance in China for AK158D1, a bispecific antibody drug conjugate targeting EGFR and TROP2 in advanced solid tumors. The clearance puts fresh attention on the company's pipeline as it pushes deeper into IO2.0 and ADC2.0. Akeso's shares recently traded at HK$90.5, up 3.37% over 90 days but down 20.12% year to date, against a consensus analyst price target of HK$158.28, with the most bullish target at HK$226.04 and the most bearish at HK$125.08. The company remains exposed to execution setbacks given its reliance on a handful of key drugs and a current net loss of CN¥967.2 million.